Highlights 4D Molecular Therapeutics, Inc.

Equities

FDMT

US35104E1001

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
24.25 ^USD	+4.30%		-8.11%	+19.69%

Apr. 15	Barclays Starts 4D Molecular Therapeutics With Overweight Rating, $45 Price Target	MT
Apr. 15	RBC Raises Price Target on 4D Molecular Therapeutics to $40 From $35, Keeps Outperform Rating, Speculative Risk Qualifier	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

4D Molecular Reports Regulatory Updates on 4D-710 For Cystic Fibrosis	Mar. 28	MT
4Dmt Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis	Mar. 28	CI
4D Molecular Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
4D Molecular Therapeutics, Inc. Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium? 2024	Feb. 12	CI
4D Molecular soars as mid-stage data for eye disease therapy 'checks all boxes'	Feb. 05	RE
4D Molecular Therapeutics Presents Positive Interim Data from Randomized Phase 2 Prism Clinical Trial of Intravitreal 4D-150	Feb. 03	CI
4D Molecular Therapeutics Receives Rare Pediatric Disease Designation from FDA for Aerosolized 4D-710 for Treatment of Cystic Fibrosis Lung Disease	Jan. 23	CI
4D Molecular Therapeutics Highlights Recent Clinical Pipeline Progress, Near-Term Milestones and Organizational Updates	Jan. 04	CI
4D Molecular Therapeutics and Arbor Biotechnologies Establish Partnership to Co-Develop and Co-Commercialize Next-Generation Genetic Medicines for CNS Diseases	Jan. 03	CI
4D Molecular Therapeutics, Arbor Biotechnologies Form Central Nervous System Disease Partnership	Jan. 03	MT
4D Molecular Therapeutics, Inc. Receives FDA Regenerative Medicine Advanced Therapy Designation for 4D-150 Genetic Medicine for Intravitreal Treatment of Wet AMD, the First RMAT Designation in Wet AMD	Dec. 21	CI
4D Molecular Therapeutics' Q3 Loss Narrows, Revenue Jumps	Nov. 09	MT
4D Molecular Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
4D Molecular Therapeutics Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Cystic Fibrosis At 2023 NACFC	Nov. 01	CI
4D Molecular Therapeutics, Inc. Announced Alignment with the U.S. Food and Drug Administration on A Plan to Lift the Clinical Hold on the Phase 1/2 Inglaxa Clinical Trial in the United States	23-10-30	CI
4D Molecular Therapeutics Says Eye Treatment Candidate Gets Priority Medicine Designation in Europe	23-10-23	MT
4D Molecular Therapeutics, Inc. Announces First Patient Enrolled in 4D-150 Phase 2 Spectra Clinical Trial in DME, and Expansion of 4D-150 Phase 2 Stage in Prism Clinical Trial in Wet AMD	23-09-07	CI
4D Molecular Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
4DMT Presents Additional Positive Interim Data from Intravitreal 4D-150 Phase 1/2 Prism Clinical Trial in Patients with Wet AMD at ASRS 2023	23-07-29	CI
4D Molecular Therapeutics Signs License Agreement With Potential Milestones-Linked Fee Options of up to $942.5 Million	23-07-11	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights 4D Molecular Therapeutics, Inc.

Equities

FDMT

US35104E1001

Highlights

Filters